| Assessment Status | Rapid Review Complete |
| HTA ID | 23067 |
| Drug | Melphalan flufenamide |
| Brand | Pepaxti® |
| Indication | Melphalan flufenamide (Pepaxti®) is indicated in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least three years from transplantation. |
| Assessment Process | |
| Rapid review commissioned | 09/11/2023 |
| Rapid review completed | 15/12/2023 |
| Rapid review outcome | A full HTA is not recommended. On the basis of current evidence, the NCPE recommends that melphalan flufenamide in combination with dexamethasone not be considered for reimbursement *. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
